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AN OVERVIEW OF THE OPIOID CRISIS AND ANALYSIS OF  
 
STANDARDIZED PATIENT EDUCATION 
 
WILLIAM W. MEIER, IV 
ABSTRACT 
Opioids have been used for the treatment of pain for hundreds of years, but recent 
increases in availability and drug potency have created an epidemic of opioid addiction 
and overdose. Between 2000 and 2015, opioid-related drug overdoses contributed to a 
reduction of 0.21 years to life expectancy in the United States. More recently, the Centers 
for Disease Control and Prevention estimated that opioids were involved in 47,600 
overdose deaths in 2017 alone, with an increasing proportion of those deaths coming 
from heroin and synthetic opioids. The United States government has been responding to 
the opioid crisis in large part by dedicating resources to the treatment of opioid overdose 
victims with naloxone and the rehabilitation of opioid addicts. The reactive nature of this 
approach, while greatly beneficial to the portion of the United States population already 
addicted to opioids, does little to prevent patients from becoming addicted to drugs in the 
first place. Teaching patients when and how to use prescriptions safely could prove to be 
a more viable strategy in addressing not only the opioid crisis but in preventing similar 
future public health crises involving prescription drugs.   
		 vi 
TABLE OF CONTENTS 
TITLE .................................................................................................................................. i 
COPYRIGHT PAGE .......................................................................................................... ii 
READER APPROVAL PAGE .......................................................................................... iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS ................................................................................................... vi	
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES ............................................................................................................ x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
INTRODUCTION .............................................................................................................. 1	
Background ..................................................................................................................... 1	
Statement of the Problem ................................................................................................ 2	
Hypothesis ...................................................................................................................... 3	
Objective ......................................................................................................................... 3	
A REVIEW OF OPIOIDS IN PAIN MANAGEMENT ..................................................... 4	
Early Forms of Pain Management .................................................................................. 4	
Pain Management in the 20th and 21st Century ............................................................... 5	
Development of Modern Pain Medication ...................................................................... 7	
The Beginning of the Opioid Crisis .............................................................................. 11	
Opioid Use Disorders, Risk Factors, and Aberrant Behaviors ..................................... 14	
Opioid Tolerance and Withdrawal ................................................................................ 18	
		 vii 
Opioid Addiction .......................................................................................................... 21	
Metabolism and Polypharmacy .................................................................................... 24	
Opioid Use in Elderly and Pregnant Patients ................................................................ 25	
Opioid Overdose and Naloxone .................................................................................... 27	
Alternative Pain Treatments ......................................................................................... 28	
Opioid-related Litigation and Criminal Investigations ................................................. 30	
Government Education Recommendations .................................................................. 33	
The Precedent for Educational Intervention in Healthcare ........................................... 34	
METHODS ....................................................................................................................... 36	
Study Design ................................................................................................................. 36	
Study Population and Sampling .................................................................................... 37	
Data Collection ............................................................................................................. 37	
Educational Intervention ............................................................................................... 38	
Data Analysis ................................................................................................................ 39	
RESULTS ......................................................................................................................... 40	
Organization and Processing of Data ............................................................................ 40	
CONCLUSION ................................................................................................................. 43	
Discussion ..................................................................................................................... 43	
Summary ....................................................................................................................... 46	
APPENDIX A ................................................................................................................... 48	
APPENDIX B ................................................................................................................... 51	
REFERENCES ................................................................................................................. 63	
		 viii 
CURRICULUM VITAE ................................................................................................... 71	
 
  
		 ix 
LIST OF TABLES 
 
Table 1: Definitions of Opioid Use Disorders .................................................................. 15 
 
 
  
		 x 
LIST OF FIGURES 
Figure 1: Map of the geographic distribution of opioid prescriptions in 2015. ................ 12 
Figure 2: 3 Waves of the Rise in Opioid Overdose Deaths .............................................. 14 
Figure 3: Characteristics of Medications for Opioid-Addiction Treatment ...................... 21 
Figure 4: Transport of different opioids across the blood-brain barrier ........................... 23 
Figure 5: Metabolic pathways for opioids ........................................................................ 24 
Figure 6: Historgram of evaluation scores before education intervention ........................ 41 
Figure 7: Histogram of evalutions scores after education intervention ............................ 42 
Figure 8: Histogram of differences between evaluation scores ........................................ 43 	
   
		 xi 
LIST OF ABBREVIATIONS 
AMA .................................................................................... American Medical Association 
APA ........................................................................................... American Pain Association 
BBB ...................................................................................................... Blood-Brain Barrier 
CBD ................................................................................................................... Cannabidiol 
CDC ................................................................. Centers for Disease Control and Prevention 
CNS .................................................................................................. Central nervous system 
CYP .......................................................................................................... Cytochrome P450 
FDA ..................................................................................... Food and Drug Administration 
HHS ........................................... United States Department of Health and Human Services 
Mdrp1 ................................................................................. Multiple drug resistant protein 1 
MOR ...................................................................................................... Mu-opioid receptor 
NAS ..................................................................................... Neonatal abstinence syndrome 
ONDCP .................................................................. Office of National Drug Control Policy 
OUD ..................................................................................................... Opioid Use Disorder 
PDMP ....................................................................... Prescription drug monitoring program 
REMS ..................................................................... Risk evaluation and mitigation strategy 
THC.................................................................................................... Tetrahydrocannabinol 
VA .................................................................. United States Department of Veteran Affairs 
WHO .......................................................................................... World Health Organization 	
 
 
 
		 1	
Introduction 
Background 
Opioids have been used for the treatment of pain for hundreds of years, but recent 
increases in availability and drug potency have created an epidemic of opioid addiction 
and overdose. Between 2000 and 2015, opioid-related drug overdoses contributed to a 
reduction of 0.21 years to life expectancy in the United States (Dowell et al., 2017). More 
recently, the Centers for Disease Control and Prevention (CDC) estimated that opioids 
were involved in 47,600 overdose deaths in 2017 alone, with an increasing proportion of 
those deaths coming from heroin and synthetic opioids (“Drug Overdose Deaths | Drug 
Overdose | CDC Injury Center,” 2019). Understanding how pain has been perceived, 
measured, and treated throughout history provides a framework for understanding how 
recent changes in patient expectations with respect to pain, drug availability to treat pain, 
and drug potency, have culminated in the current public health crisis. 
Treating acute and chronic pain is a difficult part of practicing medicine as it 
permeates all medical specialties and often requires the coordinated treatment of several 
physicians. Assessing pain also poses challenges for physicians because there is no 
quantifiable test to measure pain and assessments must be made based on patient’s verbal 
reports, creating variability based on individual pain tolerances (Meldrum, 2003). In an 
attempt to standardize the interpretation of pain, the Initiative on Methods, 
Measurements, and Pain Assessments in Clinical Trials recommends the use of the zero 
to ten pain scale where values of zero to three represents mild pain, four to six represents 
moderate pain, and seven to ten represents severe pain (Davison, 2019). This pain scale 
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and its universal interpretation helps to bring comparability to pain levels between 
patients but is still subject to variability based on each patient’s assessment and tolerance 
of pain. 
The number of patients that complain of pain has steadily risen over time. Over 
30% of Americans report some form of acute or chronic pain (Volkow & McLellan, 
2016). During this period, patients have become less tolerant of the suffering associated 
with physical pain and have increasingly requested that physicians prescribe drugs to 
manage or eliminate their pain. Consequently, the pharmacological use of opioids in the 
treatment of acute and chronic pain has also increased dramatically over the last 30 years 
with a related increase in the incidence of opioid addiction (“America’s Addiction to 
Opioids,” 2014).  
Statement of the Problem 
 The United States government has been responding to the opioid crisis in large 
part by dedicating resources to the treatment of opioid overdose victims with naloxone 
and the rehabilitation of opioid addicts. The reactive nature of this approach, while 
greatly beneficial to the portion of the United States population already addicted to 
opioids, does little to prevent patients from becoming addicted to drugs in the first place. 
Pain is increasingly cited as the reason for medical visits, and opioids remain an effective 
and important tool in treating chronic and severe pain. Therefore, the prevention of 
addiction warrants further investigation as completely discontinuing the use of opioids 
for the management of pain is unlikely in the near future.  
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Patient education is frequently recommended by government and healthcare 
agencies as an important part of addressing the opioid crisis, but the content and delivery 
of that information have remained largely the responsibility of prescribing physicians. 
The limited-time a physician is able to spend with a patient and the inconsistency of the 
information presented to patients makes it difficult to effectively communicate complex 
medical concepts. Giving patients expanded and standardized information with respect to 
the proper use of opioids could improve the transfer and retention of information, 
ultimately reducing the likelihood that a patient will transition from therapeutic use of 
opioids to substance abuse or overdose. 
Hypothesis 
 Patients participating in a standardized medical education program centered 
around prescription opioids are more likely to understand, retain, and successfully apply 
the information to safely use prescription opioids. 
Objective 
This thesis will provide an overview of the use of opioids in pain management 
and evaluate the efficacy of a standardized patient education system with respect to 
opioids based on the information and recommendations set forth by government and 
healthcare agencies. The main objective of the educational program is to provide patients 
with a general understanding of how to responsibly and safely use opioids for the 
management of their pain. 
		 4	
A Review of Opioids in Pain Management  
Early Forms of Pain Management  
The use of opium for the treatment of pain has been around for thousands of 
years, with the earliest record of its cultivation dating back to around 5000 B.C. in Asia 
Minor (Aragon-Poce et al., 2002). From there, the use of opium spread to Greek, Roman, 
and Islamic cultures where it was used for its calming and anesthetic properties (Aragon-
Poce et al., 2002). The use of opium to treat pain spread to every major civilization in 
Europe and Asia and eventually was introduced into the colonies that became the United 
States of America.  
In the early 1600s, physicians began using laudanum, a mixture of opium and 
sherry, as a treatment for pain. This treatment protocol changed in the early 1840s when 
ether and chloroform began to be used as common anesthetics. (Collier, 2018; Meldrum, 
2003). The anesthetic properties of chloroform and ether, and their ability to render a 
patient unconscious allowed surgeons to undertake more complex and prolonged 
operations. Patients quickly embraced the idea of being unconscious during procedures 
because it addressed both pain and the potential for psychological trauma during 
procedures. Using these new compounds came with resistance from certain physicians 
who worried about operating on unconscious patients and the effect these anesthetics 
could have on patients in the short and long-term (Meldrum, 2003). The prevailing 
cultural beliefs surrounding pain also offered resistance to the use of ether and 
chloroform as pain was commonly believed to be a positive “sign of the patient’s vitality 
[and] of the prescription’s effectiveness” (Meldrum, 2003). However, these scientific and 
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cultural objections were ultimately overcome by the desire of both physicians and 
patients to relieve chronic and acute pain.  
Morphine was first isolated from the opium poppy in 1804 by the German 
scientist Friedrich Serturner (Meldrum, 2003). Industrial production of morphine began 
in Germany in the 1820s and in the United States nearly a decade later (Meldrum, 2003). 
At that time, morphine was readily available over the counter in the United States in the 
form of liquids, pills, and “headache powders” (Meldrum, 2003). The use of morphine 
exploded between 1861 and 1865 as soldiers in the Civil War consumed an estimated 10 
million opium pills and over 80 tons of opium powders and liquids to deal with war-
related injuries (Lewy, 2014). Following the Civil War, physicians began to express 
concerns about “morphine habits” expressed by soldiers and civilian users (Meldrum, 
2003).  
Pain Management in the 20th and 21st Century 
In 1898, Bayer Company of Germany introduced a new form of morphine, 
diacetylated morphine, under the trademark name Heroin for use as a cough remedy 
(Meldrum, 2003). Heroin was initially thought to be less addictive than traditional 
morphine, but the public quickly learned that heroin pills could be crushed and inhaled in 
order to get high. The escalation of heroin’s use as a street drug led to the passage of the 
Harrison Narcotics Tax Act in 1915, which taxed and restricted the sale of coca, opium 
and their derivatives (Meldrum, 2003). Physicians could still prescribe these compounds 
for the treatment of pain, but could not prescribe them for the maintenance of a patient’s 
addiction (Meldrum, 2003). These restrictions led to an increase in addiction-related 
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crime which sparked the revision of the Harrison Narcotics Tax Act in 1924, banning the 
importation of heroin completely (Meldrum, 2003). Thereafter, opioids were strictly 
regulated and reserved only for severe pain and cancer-related pain. Between 1915 and 
1938 more than 5,000 physicians were convicted, fined or jailed for providing patients 
with drugs for the maintenance of addiction (Trebach, 1982). During the 1930s to the 
1960s, the use of certain drugs including opioids, marijuana, and cocaine was increasing 
criminalized and enforced with stronger penalties (“The United States War on Drugs,” 
2019). Nevertheless, in the 1960s and 70s, the counterculture movement in the United 
States popularized the use of these drugs, thereby greatly increasing demand and spurring 
the modern war on drugs.  
Recreational drug use has remained a major issue throughout the 20th century 
with particular attention being drawn to marijuana and cocaine by President Richard 
Nixon’s “War on Drugs” campaign, which began in 1971 (“The United States War on 
Drugs,” 2019). In that same year, President Nixon began federal funding for controversial 
methadone maintenance programs (“The United States War on Drugs,” 2019). Two years 
later, in 1973, the Drug Enforcement Agency was created and initially tasked with 
closing the Mexico border to the importation of marijuana (“The United States War on 
Drugs,” 2019). Since then, the Drug Enforcement Agency’s mandate, powers, and 
jurisdiction have materially expanded. Despite the U.S. government’s hard stance against 
drug use, the general acceptance of using opioids to manage pain was largely unchanged 
due to the government’s focus on marijuana and cocaine (Musto, 1991). In 1981, 
President Ronald Reagan increased funding for drug eradication and interdiction 
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programs but cut funding for programs of patient education and rehabilitation (“The 
United States War on Drugs,” 2019). In 1988, the Anti-Drug Abuse Act established the 
Office of National Drug Control Policy in the Executive Office of the President 
(ONDCP) and released funding for community-based drug prevention grants (National 
Narcotics Leadership Act, 1988). However, these governmental initiatives again focused 
on marijuana and cocaine, generally ignoring the use of opioids, other than heroin. 
Development of Modern Pain Medication 
Opioid types are determined by the method in which the opioid is produced or 
isolated. It is important to be able to differentiate between the types of opioids primarily 
because of their potency. However, the opioid type is usually not considered in the 
decision to prescribe one over another. There are three types of opioids: natural opiates, 
semi-synthetic opioids, and synthetic opioids (“Narcotics (Opioids) | DEA,” 2019). 
Natural opiates are naturally occurring alkaloids found in the opium poppy (“Narcotics 
(Opioids) | DEA,” 2019). Examples of natural opiates include morphine, codeine, and 
thebaine. Semi-synthetic opioids are man-made opioids created from natural opiates 
(“Narcotics (Opioids) | DEA,” 2019). Examples of semi-synthetic opioids include 
hydromorphone, hydrocodone, oxycodone (OxyContin), and heroin. Synthetic opioids 
are chemically made without natural opiates (“Narcotics (Opioids) | DEA,” 2019). 
Examples of synthetic opioids include fentanyl, methadone, and tramadol (“Opioid 
Misuse | Massachusetts Technical Assistance Partnership for Prevention,” 2019). 
Below is a list of currently available semi-synthetic and synthetic opioids with a brief 
description of each: 
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• Buprenorphine is a semi-synthetic analgesic used for the treatment of opioid 
addiction and for the management of moderate to severe chronic pain (“What 
exactly is Buprenorphine?,” 2019). Buprenorphine is a partial opioid agonist with 
a higher affinity for opioid receptors than other opioids, meaning that it is less 
potent than other opioids like heroin and can displace other opioids from receptors 
(“What exactly is Buprenorphine?,” 2019). These characteristics result in less 
euphoria and potential for respiratory depression as compared to other opioids, making	this	drug	a	good	choice	for	addiction	therapy. 
• Fentanyl is a powerful synthetic opiate analgesic similar in structure to other 
opioids, but 100 times more potent than morphine (“Fentanyl,” 2019). This drug 
is generally used to treat patients with acute postoperative pain and in some cases 
to treat patients with tolerance to other opioids (“Fentanyl,” 2019). This drug is 
addictive and has a significant risk of fatal overdose if taken improperly. Fentanyl 
is also commonly mixed with street drugs for its ability to produce stronger highs 
with lower costs (“Fentanyl,” 2019).  
• Heroin is a semi-synthetic opiate drug that is made from morphine that is 
naturally extracted from poppy plants (“Heroin,” 2019). It was first isolated in 
1898 by Bayer Company of Germany and data collected in 2011 showed that 80 
percent of heroin users started their drug use by misusing prescription opioids 
(“Heroin,” 2019; Meldrum, 2003). Recent data has shown an increase in heroin 
use that may be related to increased governmental regulation of prescription 
opioids (“Overdosing on Regulation,” 2019). 
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• Hydrocodone is a semi-synthetic opioid dosed in an extended-release formula for 
the management of pain all day long (“Hydrocodone,” 2019). Hydrocodone has a 
significant risk of addiction with prolonged use and should not be paired with 
other long or short-acting opioids (“Hydrocodone,” 2019). Hydrocodone is also 
sometimes combined with other drugs such as acetaminophen. 
• Hydromorphone is a semi-synthetic opioid analgesic similar in effect to 
hydrocodone but more potent. Hydromorphone is recommended to be used for 
patients who have become tolerant to other opioids or respond poorly to other 
available opioids (“Hydromorphone,” 2019).  
• Methadone is a synthetic opioid that is similar in effects to morphine, but longer-
lasting and is often used as a substitute drug to treat withdrawal symptoms and aid 
in the recovery from opioid addiction (“Methadone,” 2015). Methadone is used in 
a similar manner to buprenorphine for medically-assisted treatment.  
• Oxycodone is a semi-synthetic opioid used to relieve moderate to severe pain with 
similar risks for overdose and addiction as compared to other full agonist opioids 
(“Oxycodone,” 2019). Oxycodone is often combined with other drugs such as 
acetaminophen and ibuprofen and is the opioid used in Purdue Pharma’s extended 
released pain medication OxyContin (“Oxycodone,” 2019).  
Common side effects for all of these drugs include: constipation, weakness, 
headache, nausea or vomiting, loss of appetite, weight gain, stomach pain, sore tongue, 
dry mouth, sweating, flushing, mood changes, difficulty urinating, vision problems, 
decreased sex drive, missed menstrual periods, difficulty falling asleep or staying asleep, 
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and respiratory depression (“Fentanyl,” 2019; “Hydrocodone,” 2019; “Hydromorphone,” 
2019; “Methadone,” 2015; “Oxycodone,” 2019; “What exactly is Buprenorphine?,” 
2019). 
The most significant pharmacological breakthrough, as it relates to the expanded 
use of opioids to treat pain, was made by Purdue Pharma with the development of the 
Contin drug release system which allowed for the sustained release of drugs (Leslie, 
1986). The Contin system was combined with the previously developed semisynthetic 
opioid oxycodone to produce OxyContin. This new drug was revered for its ability to 
relieve chronic pain with less frequent dosing and reduced abuse potential as compared 
with the immediate-release form oxycodone. Purdue Pharma supported these claims by 
citing studies from Perry & Heidrich and Porter & Jick who each found the incidence of 
iatrogenic addiction from narcotics to be zero or near zero percent for the patients 
included in their individual studies (Perry & Heidrich, 1982; Porter & Jick, 1980; Van 
Zee, 2009).  However, these studies examined populations of patients in hospitals where 
they received dosing and supervision from medical professionals. These findings do not 
directly support the notion that iatrogenic addiction rates are equally low for patients in a 
self-dosing chronic pain management regime (Van Zee, 2009). In addition, Purdue 
Pharma used aggressive marketing techniques, including promoting and underwriting 
pain-management seminars for physicians and paying lucrative bonuses to sales 
personnel to gain physician and public acceptance of OxyContin, thereby increasing sales 
of the drug.  
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The push to sell OxyContin came at the same time that pain was considered 
widely undertreated. The American Pain Society Quality of Care Committee published a 
statement in 1995 that contributed to the establishment of pain as the “fifth vital sign” in 
2001, bringing unprecedented attention to the treatment of pain (Gordon et al., 2005). 
That same year, OxyContin’s label was changed to strengthen warnings about the risk of 
misuse and abuse (Timeline of Selected FDA Activities & Significant Events Addressing 
Opioid Misuse & Abuse, 2019). As the treatment of acute and chronic pain became more 
commonplace and more accepted, patients began to expect little to no pain in daily life 
and reported pain more frequently to their physicians. In 2003, the Food and Drug 
Administration (FDA) issued a warning to Purdue Pharma for misleading OxyContin 
advertisements that minimized the severity of the risks associated with the drug’s use.  
The Beginning of the Opioid Crisis 
By 2009, over one million emergency department visits were related to the misuse 
or abuse of pharmaceuticals; an increase of over 98% in less than five years (Timeline of 
Selected FDA Activities & Significant Events Addressing Opioid Misuse & Abuse, 2019). 
A cross-sectional survey in 2010 found that 30.7% of adults in the United States were 
living with chronic pain (Johannes, Le, Zhou, Johnston, & Dworkin, 2010).  In response, 
prescriptions for opioids increased dramatically. In 2012, the number of opioids 
prescribed peaked at over 255 million pills with a prescription rate of 81.3 per 100 
persons in the United States (“U.S. Opioid Prescribing Rate Maps | Drug Overdose | CDC 
Injury Center,” 2019). An analysis of the geographical distribution of these prescriptions 
makes it clear that some states received a disproportionate amount of prescriptions per 
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capita. For example, Alabama, West Virginia, and Tennessee had prescription rates of 
143.8, 136.9, and 136.1 per 100 persons respectively (“U.S. Opioid Prescribing Rate 
Maps | Drug Overdose | CDC Injury Center,” 2019). An opioid prescription density map 
can be found below in Figure 1. In 2016, the CDC issued the first guidelines for 
prescribing opioids for chronic pain unrelated to cancer treatment and end-of-life care 
(Dowell et al., 2016). 
 
 
 
Figure 1: Map of the geographic distribution of opioid prescription in 2015 by state (“U.S. 
Opioid Prescribing Rate Maps | Drug Overdose | CDC Injury Center,” 2019). 
One year later, the United States Department of Health and Human Services 
(HHS) declared the opioid crisis a public health emergency and detailed a five-point plan 
to address the problem (Affairs (ASPA), 2017). The five-point plan included: 1) 
improving access to treatment and recovery services 2) promoting the use of overdose-
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reversing drugs like naloxone 3) improving public health surveillance 4) supporting 
research on pain and addiction and 5) advancing better practices for pain management 
(“Secretary Price Announces HHS Strategy for Fighting Opioid Crisis,” 2017). The 
effectiveness of this program has yet to be determined.  
Between 1999 and 2017 more than 700,000 people in the United States died from 
a drug overdose, with prescription and illicit opioids contributing to roughly 68 percent of 
those deaths (“Drug Overdose Deaths | Drug Overdose | CDC Injury Center,” 2019). The 
number of opioid-related deaths has also increased each year with a growing proportion 
of deaths coming from heroin and synthetic opioids like fentanyl (“Overdosing on 
Regulation,” 2019; Weiner, Malek, & Price, 2017). It is believed that this trend is due to 
the implementation of strict legal regulations and medical treatment protocols related to 
prescribing opioids that have limited the number of available drug prescriptions, causing 
prescription opioid abusers to transition to the use of heroin, which is cheaper and more 
readily available (“Overdosing on Regulation,” 2019). An illustration of the increase in 
opioid deaths attributable to certain opioids can be found below in Figure 2. 
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Figure 2: 3 Waves of the Rise in Opioid Overdose Deaths (“Drug Overdose Deaths | Drug 
Overdose | CDC Injury Center,” 2019). 
 
The combination of aggressive marketing, misinformation, changing cultural 
beliefs about pain, increased patient demand, and the liberal use of opioids for pain all 
contributed to the creation of the opioid crisis. It also appears that the policies and 
regulations created to address the crisis may be unintentionally forcing opioid addicts to 
turn to unregulated and more dangerous street drugs. 
Opioid Use Disorders, Risk Factors, and Aberrant Behaviors 
It is important to be able to differentiate between patient behavior and 
uncontrollable physical adaptations, but the terms used to describe these conditions are 
often erroneously used interchangeably. For example, the term “physical dependence” 
has the connotation of addiction and abuse but actually refers to a physical adaptation 
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characterized by the potential for experiencing withdrawal symptoms (Burcher, Suprun, 
& Smith, 2018). To avoid confusion, a list of the standard terms associated with Opioid 
Use Disorders (OUD) can be found in Table 1 below. 
    
Table 1: Definitions of Opioid Use Disorders (Burcher et al., 2018). 
In response to the increasing number of patients suffering from OUDs, physicians 
are making a concerted effort to try and identify the symptoms and behaviors surrounding 
OUD to help appropriately guide the treatment of patients with OUD (Burcher et al., 
2018). Below is a list of risk factors associated with OUD. When evaluating a patient for 
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OUD, the presentation of any risk factor should be understood in the context of the 
patient’s medical history and treatment plan before determining that a patient has OUD. 
 
Risk Factors for Opioid Use Disorder (Burcher et al., 2018; Ives et al., 2006): 
• History of substance abuse 
• Any physical maladies 
• Mental health history 
• Sedative/hypnotic use 
• Depression 
• Alcohol abuse history 
• Anti-depressant use 
• Male gender 
• Single 
• Race (white, non-Hispanic) 
• Comorbidity of mental health and physical condition 
• High-intensity opioid therapy 
• Preoperative opioid use 
• High self-assessed risk of addiction 
• Tobacco use 
• A family history of substance abuse 
• Low socioeconomic status 
• Use of ACE-inhibitors 
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Aberrant Drug-Related Behaviors may also indicate that a patient has become 
addicted to opioids. Below is a list of aberrant patient behavior that may indicate 
prescription medication abuse or addiction. 
Types of Aberrant Drug-Related Behaviors (Merlin et al., 2014): 
• Patients requesting opioids, including requests for specific opioids or dosages 
• Obtaining non-prescription opioids 
• Emergency room visits related to opioids 
• Patient emotions related to opioids 
• Lost or stolen opioids 
• Running out of opioids early 
• Inconsistent urine drug screens (negative for opioids, positive for an illicit 
substance, or both) 
• Multiple opioid prescribers 
• Illicit substance use 
• Injecting medications meant for oral use; oral or IV use of transdermal patches 
• Resistance to changing medications despite a deterioration in function or 
significant negative effects 
• Falsification of prescription (forgery or alteration) 
• Patient threats related to opioids 
• Patient selling opioids (“diversion”) 
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When assessing a patient, some behaviors may appear to be aberrant but may actually 
be part of stabilizing a patient’s pain condition. These behaviors may require further 
investigation before classifying them as aberrant drug-taking behavior. Those behaviors 
to be considered by physicians when assessing patient behaviors includes the following 
(Merlin et al., 2014): 
• Asking for or demanding more medication 
• Asking for specific medications 
• Stockpiling medications during times of less severe pain 
• Use of the pain medication to treat other symptoms 
• Reluctance to decrease opioid dosing once stable 
• In the early stages of treatment 
o Increasing medication dosing without instruction to do so from the 
provider 
o Obtaining prescriptions from sources other than primary pain provider 
o Sharing or borrowing similar medications from friends/family 
Proper assessment and classification of patient behaviors remain challenging, but 
they have recently benefited from increased awareness and study from researchers. 
However, much like the assessment of pain, the variability in patient behaviors will 
continue to complicate the recognition of OUDs.  
Opioid Tolerance and Withdrawal 
Tolerance is defined as a state in which an organism experiences a reduced effect 
from a drug that has been repeatedly administered over time (Siegel, 2005). When 
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patients use prescription opioids or heroin repeatedly over time, they are at risk of 
developing tolerance. This reduction in effect requires increases in dosage or changing of 
the prescribed opioid to regain the same type of response and analgesic effects 
experienced when first taking the drug (Siegel, 2005). Over time, tolerance continues to 
escalate and can reach a level where a large dosage for a frequent user and low dosage for 
an inexperienced user could be equally safe and elicit the same level of anesthetic effect 
for each patient respectively (Siegel, 2005). The danger associated with tolerance is that 
patients with larger doses share their medication with less experienced and less tolerant 
users who could then potentially overdose on the shared prescription.  
The three types of tolerance are described below (Siegel, 2005): 
1. Short-term tolerance: tolerance which is triggered by repeated exposure to 
a drug over a short period of time. Cocaine use is an example of short-
term tolerance as the first time using it is the most intense. Tolerance to 
cocaine builds almost immediately and subsequent uses will elicit a 
relatively decreased level of effect as compared to the first use.  
2.  Long-term tolerance: sometimes referred to as chronic tolerance, develops 
when a person’s brain adapts to the repeated exposure of drugs. This type 
of tolerance develops over a period of weeks or months. Patients using 
opioids for their euphoric properties will over time develop chronic 
tolerance causing users to increase the dosage or find new ways to 
administer the drug through snorting or injection in an attempt to regain 
the euphoric effect. 
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3. Learned tolerance: results from the practicing of a task while under the 
influence of medication and can accelerate the development of tolerance. 
Studies have shown that groups given a task under the influence of alcohol 
develop tolerance to the alcohol more quickly than groups that are given 
alcohol without a task. A similar phenomenon applies to the use of 
prescription opioids.  
Withdrawal is defined by the WHO as “a group of symptoms of variable 
clustering and degree of severity which occur on cessation or reduction of the use of a 
psychoactive substance that has been taken repeatedly, usually for a prolonged period 
and/or in high doses” (“WHO | Withdrawal state,” 2019). Withdrawal is very closely 
related to the symptoms of tolerance. When drugs are used repeatedly over a period of 
time, tolerance leads to the attenuation of the body’s response. Withdrawal is the 
manifestation of symptoms created by the full expression of previously attenuated 
processes (Burcher et al., 2018). The body anticipates the presence of the drug and 
continues the processes associated with attenuation causing the withdrawal symptoms. 
For opioid withdrawal, these symptoms include muscle cramps, chills, and 
gastrointestinal distress. The presence of these negative symptoms often leads patients to 
continue the use of opioids as a means to relieve the withdrawal symptoms. The presence 
of withdrawal symptoms is one of the indicators for a physical dependence on opioids.  
Physicians aim to treat or minimize the effects of withdrawal symptoms when 
helping patients recover from opioid addiction. Methadone, buprenorphine, and 
naltrexone are the medications used for the medically-assisted treatment of addiction. 
		 21	
These three drugs are long-acting and do not produce euphoric, tranquilizing, or analgesic 
effects when dosed appropriately, making them ideal candidates for medically-assisted 
treatments. Figure 3 below details the differences and use cases of methadone, 
buprenorphine, and naltrexone in medically-assisted treatment. 
 
Figure 3: Characteristics of Medications for Opioid-Addiction Treatment (Volkow, Frieden, 
Hyde, & Cha, 2014) 
 
Opioid Addiction 
Addiction is characterized as a multidimensional disease with both 
neurobiological and psychosocial dimensions that contribute to risky and long term drug 
use (Savage et al., 2003). When heroin or any other opiate enters the bloodstream, they 
first need to cross the blood-brain barrier (BBB) before producing their analgesic effect 
(Schaefer et al., 2017). The BBB acts as a semipermeable membrane comprised of 
endothelial cells that rely on transport proteins to move nutrients into the brain (Schaefer 
et al., 2017). An opioid’s effectiveness is therefore dependent on its ability to permeate 
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the BBB. Counteracting the transport of opioids across the BBB to the brain is P-
glycoprotein, also known as multiple drug-resistant protein 1 (Mdr1), which works to 
expel opioids and other substrates (Schaefer et al., 2017). Therefore, the overall efficacy 
of an opioid is determined by a balance between its relative ability to permeate the BBB 
and the speed at which Mdr1 is able to expel the opioid. Morphine is used as the 
international standard on which the potency of other opioids are determined (Schaefer et 
al., 2017). Heroin, for reference, has been determined to be twice as potent as morphine 
due to its acetylation and resulting increased lipophilicity (Schaefer et al., 2017). 
Additionally, fentanyl has a significant role in contributing to opioid deaths because its 
potency is 100 times that of morphine, allowing very small doses to result in an overdose 
(Schaefer et al., 2017). Figure 4 illustrates the ability of different opioids to cross the 
BBB with representative luminal and cytosolic concentrations. 
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Figure 4: Transport of different opioids across the blood-brain barrier (Schaefer et al., 
2017).  
Once opioids cross the BBB they bind to mu-opioid receptors (MORs) activating 
biochemical pathways that create a sense of pleasure (Kosten & George, 2002; Schaefer 
et al., 2017). One of the pathways activated is the mesolimbic reward system which 
generates signals in the ventral tegmental area resulting in the release of dopamine in the 
nucleus accumbens which causes the feeling of pleasure (Kosten & George, 2002). It is 
this feeling of pleasure that sometimes causes opioid users to continue using the drug past 
its therapeutic application. These learned associations between opioid use and pleasure 
strengthen with repeated use and can contribute to drug cravings and addiction (Volkow 
& McLellan, 2016). 
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Metabolism and Polypharmacy 
Opioids are generally metabolized by phase I metabolism via the Cytochrome 
P450 (CYP) pathway, phase II metabolism via conjugation, or a combination of both 
(Smith, 2009). The difference between these two pathways is significant as drugs 
processed via the CYP pathways are much more likely to have drug-drug interactions. 
More specifically, CYP3A4  is responsible for processing more than 50 percent of all 
drugs as well as certain opioids (Savage et al., 2003). Tramadol, methadone, fentanyl, 
and oxycodone are all processed via the CYP pathway and are therefore the opioids most 
likely to have drug-drug interactions. In contrast, Morphine, oxymorphone, and 
hydromorphone are all processed via conjugation and are therefore less likely to 
contribute to drug-drug interactions. An illustration of drug metabolism and a drug’s 
potential for drug-drug interactions can be found below in Figure 5. 
 
 
Figure 5: Metabolic pathways for opioids involve either phase 1 or phase 2 metabolism, 
which impacts potential for drug interactions and unpredictable clinical response (Davison, 
2019). 
 
		 25	
 Physicians must account for the type of metabolism when prescribing opioids to 
patients who are taking other medications since polypharmacy reactions can be life-
threatening. Additionally, patients with hepatic or renal function deficiencies may require 
additional considerations since their inability to process and/or clear drugs from the body 
may signal the relative or absolute contraindication of certain drugs.  
Opioid Use in Elderly and Pregnant Patients 
Special considerations must be made when prescribing opioids to elderly and 
pregnant patients. Elderly patients provide a particularly difficult challenge when 
prescribing opioids because of the demographic’s increased prevalence of pain (25-50 
percent of community-dwelling elderly), high incidence of polypharmacy, and the 
changes in pharmacokinetics and pharmacodynamics that occur with age (Chau et al., 
2008; Gerlach et al., 2017). Despite these considerations, opioid prescriptions for elderly 
patients have continued to rise. Since 2004, patients 65 and older have seen a marked 
increase in the number of central nervous system (CNS) polypharmacy medical visits 
which include opioids. In 2013, 76.2 percent of CNS polypharmacy visits in older adults 
included an opioid, making opioids the most common component of CNS polypharmacy 
(Gerlach et al., 2017). Therefore, it is recommended that elderly patients being prescribed 
opioids should start at one-quarter to one-half the standard dosage of a younger patient 
with greater attention being given to drug-drug interaction (Chau et al., 2008).  
Pregnant women are the other major demographic that requires special attention 
when considering the use of opioids. Pregnant women often experience pain related to 
their pregnancy in the form of back and pelvic pain, resulting in medical visits centered 
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around pain management. When deciding how to best treat pain in pregnant women, both 
the health of the mother and the unborn child must be taken into consideration before 
prescribing opioids. The American Pain Society (APA) recommends no use or minimal 
use of opioids during pregnancy due to a variety of complications that can arise. Using 
opioids during pregnancy can result in altered fetal growth, preterm birth, congenital 
heart defects, neural tube defects, as well as other birth defects (Patrick et al., 2015; 
Stover & Davis, 2015; Yazdy et al., 2015). Consequently, most physicians will not 
prescribe opioids to pregnant patients. 
However, there are scenarios in which it may be necessary to use opioids during 
pregnancy. For example, if a woman is a long-term user of prescription opioids or heroin 
and becomes pregnant, using therapies such as methadone maintenance therapy and 
buprenorphine maintenance therapy have been shown to improve prenatal care 
adherence, reduce fetal death, and result in higher infant birth weight (Yazdy et al., 
2015). Infants born after being exposed to opioids in the womb are also at risk for 
developing neonatal abstinence syndrome (NAS). This condition is characterized by CNS 
hyperirritability, autonomic nervous system dysfunction and gastrointestinal disturbances 
(Stover & Davis, 2015). Infants diagnosed with NAS often require prolonged 
hospitalization and therapy with morphine to ease symptoms (Jansson & Velez, 2012; 
Yazdy et al., 2015).  
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Opioid Overdose and Naloxone 
 Even though the overall prescribing rates of opioids have continued to fall since 
2012, opioid-related overdose deaths continue to rise. Opioids accounted for 67.8 percent 
(47,600 deaths) of the 70,237 drug overdoses in the United States in 2017, representing a 
9.6 percent increase from the previous year. (“Drug Overdose Deaths | Drug Overdose | 
CDC Injury Center,” 2019). To address this growing problem, state and local 
governments are distributing the opioid antagonist naloxone to first responders. Naloxone 
comes in the form of an injection or nasal spray and is capable of quickly reversing an 
opioid overdose by displacing the drug from MORs in the brain (Chhabra & Aks, 2017). 
Distribution of naloxone to first responders is critical to reducing drug overdoses since 
they are usually the first to arrive at the scene of an overdose. A study in Erie County, 
New York found that 90.9 percent of drug users were unresponsive when first responders 
arrived at the scene. Using naloxone, first responders were able to successfully reverse 
81.5 percent of these overdoses (Heavey, Delmerico, et al., 2018).  
Distribution of naloxone to the public is a possible next step in further reducing 
the number of opioid overdose deaths. It is estimated that between 56 percent and 85 
percent of heroin users witness an overdose (Heavey, Delmerico, et al., 2018). Despite 
the documented effectiveness of naloxone, less than half of individuals polled at a 
substance use treatment center in New York State had ever had access to a naloxone kit 
(Heavey, Chang, et al., 2018). Opioid dosage and response time are two critical factors in 
determining the effectiveness of naloxone in any given scenario. Therefore, providing 
heroin users with naloxone kits and naloxone training at needle exchanges could help 
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increase the survival rate of overdose victims by reducing the time between overdose and 
naloxone administration (Chhabra & Aks, 2017). While naloxone is more frequently used 
to reverse heroin overdose, it is equally effective at reversing prescription drug overdose 
and can be administered by anyone with minimal training. Naloxone intervention can 
save lives in the short-term and give patients the opportunity to recover from addiction in 
the long-term. 
Alternative Pain Treatments 
Physicians are more regularly recommending alternative treatments to opioids for 
the management of pain in an effort to reduce the risk of opioid addiction and overdose. 
These alternative treatments can range from over the counter medications to advanced 
minimally invasive procedures. Physical therapy and acupuncture may help increase 
mobility and reduce pain for certain conditions, but may need to be paired with other 
forms of pain management for improved pain relief (“Non-Opioid Treatment for Chronic 
Pain—When Seconds Count,” 2019).  
Acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) are over the 
counter medications that are often used in combination with prescribed opioids. 
However, these medications are suitable for the treatment of pain on their own (Laguerre, 
2013). Both drugs have potential side effects: acetaminophen can impact hepatic health if 
taken at high doses and ibuprofen can cause gastrointestinal symptoms and bleeding if 
used long-term (Laguerre, 2013). Studies have shown that the combination of both 
acetaminophen and ibuprofen has been able to reduce pain as effectively as oxycodone, 
hydrocodone, and codeine two hours after administration (Slawson, 2018).  
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There are also a variety of minimally invasive procedures that are effective in the 
management of pain. Nerve block injections use numbing medication at locations 
dependent on the pain to block or dampen signals of pain (Richman et al., 2006). Nerve 
blocks have been shown to be effective at blocking and preventing chronic pain in a 
manner similar to opioids with a decrease in the potential for side effects (Richman et al., 
2006). Another minimally invasive procedure, radiofrequency ablations, involves burning 
nerves responsible for pain signaling to effectively “short-circuit” the pain signal (Toyota 
et al., 2005). Radiofrequency ablation has been shown to be effective at relieving pain for 
as long as one year after the procedure (Toyota et al., 2005).  
Transcutaneous electrical nerve stimulation is a non-invasive alternative to 
opioids that uses electrical stimulation on the skin to activate afferent fibers to reduce 
neuropathic pain (Sluka & Walsh, 2003). While electricity has been used as an analgesic 
for hundreds of years, clinical studies analyzing the effectiveness of transcutaneous 
electrical nerve stimulation are not in agreement. Some clinical studies have found the 
electrical stimulation to be effective at managing pain while other studies have found no 
effect on pain at all (Sluka & Walsh, 2003). However, because of its non-invasive nature 
and ease of use, transcutaneous electrical nerve stimulation is an alternative treatment to 
opioids worth exploring before progressing to more invasive or risky procedures.  
Cannabis is also being used as an alternative to opioids but has not received 
widespread adoption because it remains federally illegal despite the legalization of 
marijuana by certain states. Cannabis contains three active compounds: Delta-9-
tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (Bennett, Paice, & 
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Wallace, 2017). THC is the most abundant compound in cannabis best known for its 
psychoactive properties valued in recreational use (Bennett et al., 2017). CBD is the 
second most abundant compound in cannabis and is recognized to have a larger medical 
application with studies showing that CBD can assist in the effective treatment of 
seizures, muscle spasms, and inflammation without causing psychoactive effects (Bennett 
et al., 2017). A recent retrospective cross-sectional survey of patients with chronic pain 
using cannabis showed a 64 percent decrease in opioid use, a decrease in side effects, and 
overall improvements in quality of life (Bennett et al., 2017). Absorption of both THC 
and CBD can be highly variable depending on the administration method. As with other 
therapies, cannabinoids have associated risks and side effects which include: sedation, 
dizziness, dry mouth, cognitive impairment, and anxiety (Bennett et al., 2017). The 
ability to further study the potential benefits of CBD and cannabis, in general, is 
significantly limited by federal regulations surrounding the Schedule I status of 
cannabinoids. Legalization or rescheduling of cannabinoids would allow new research 
into the effectiveness and relative risks associated with using cannabis for the treatment 
of pain.  
Opioid-related Litigation and Criminal Investigations 
 Purdue Pharma and other pharmaceutical companies and drug distributors are 
facing numerous legal actions for their part in contributing to the opioid crisis. Purdue 
Pharma will be used as an illustration in order to give perspective as to the mounting civil 
litigation response to the opioid crisis. Purdue Pharma first faced significant legal action 
in 2007, when the company was accused of misstating facts about the risks associated 
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with OxyContin (Childers, 2019). In that case, top officials from Purdue Pharma pled 
guilty to the allegations, and as a result, agreed to pay over $600 million to settle the 
lawsuit (Childers, 2019). However, the admittance of guilt and substantial monetary 
penalty did little to affect the growing opioid crisis as the number of opioid prescriptions 
continued to climb, ultimately peaking in 2012. 
 In 2015, the State of Mississippi was the first state to sue Purdue Pharma for its 
alleged role in the opioid crisis. Between 2015 and 2019, 48 states and the District of 
Columbia also filed lawsuits against Purdue Pharma alleging the pharmaceutical maker 
contributed to and sustained the opioid crisis (Paavola, 2019). In response to the 
escalating financial exposure created by these lawsuits, on September 15, 2019, Purdue 
Pharma filed for Chapter 11 bankruptcy as part of its plan to restructure the company into 
a public benefit trust through a tentative settlement agreement (Hoffman & Walsh, 2019). 
The proposed public benefit trust would distribute profits from the sale of its drugs, 
including OxyContin, to pay plaintiffs’ claims and support the research and development 
of drugs to treat overdose and addiction (Hoffman & Walsh, 2019). Purdue Pharma 
valued the proposed settlement at $10 billion, including $3 billion of which would be 
paid by the Sackler family which owns the privately-held company (Hoffman & Walsh, 
2019). However, not all plaintiffs believe this settlement is appropriate for the damages 
caused by Purdue Pharma’s role in the opioid crisis. Some estimates put the total 
damages of the opioid crisis at $78.5 billion per year when accounting for productivity 
losses, addiction treatment, healthcare costs, and criminal justice involvement (Childers, 
2019). Using those estimates, the proposed settlement would fall significantly short of 
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Purdue Pharma’s proportionate share of the estimated overall damages. The case is 
ongoing and will likely take several more years to reach a resolution.  
Recently, federal and certain state prosecutors have also initiated criminal 
investigations as to whether certain pharmaceutical companies intentionally allowed 
opioids to be used for non-medical purposes (Ramey, 2019). Prosecutors are examining 
whether these companies may have violated the federal Controlled Substances Act as 
well as comparable state statutes related to the manufacture and distribution of 
prescription drugs (Ramey, 2019). Under these laws, drug companies are generally 
required to monitor drugs that are subject to abuse by reporting suspicious or unusual 
orders and disclosing suspect pharmacy customers to the appropriate governmental 
agency (Ramey, 2019). Pharmaceutical companies may face both civil and criminal 
sanctions if they are ultimately found to have violated such laws.  
 In addition to the lawsuits brought against pharmaceutical companies and drug 
distributors, prescribing physicians are also being targeted in individual and government 
lawsuits. So far, the limited number of targeted physicians have been accused of illegally 
prescribing or distributing opioids with some successful convictions (Masterson, 2019). 
These lawsuits affect only a small minority of the medical community, but their looming 
presence has had a decisive impact on the prescribing practices of physicians. Where pain 
was once recognized as undertreated due to a lack of recognition, it is now undertreated 
due to a conscious reduction in prescribing (Davison, 2019). Strict government 
regulations, the use of Prescription Drug Monitoring Programs (PDMPs), and physicians’ 
fear of legal retribution have led to a general reluctance to prescribe opioids. This 
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prescriber reluctance has reduced the overall number of opioids prescribed but has also 
had the unintended consequence of restricting the distribution of opioids to patients who 
truly need them for the treatment of their pain. The fear of contributing to addiction or 
enabling opioid abuse has restricted the prescribing of opioids to patients who could 
benefit from them.  
Government Education Recommendations 
 It is the recommendation of the CDC, FDA, ONDCP, Department of Veteran 
Affairs (VA), American Pain Society (APS), and American Medical Association (AMA) 
that patient education be used as part of a risk mitigation strategy to address the opioid 
crisis. However, despite the universal recognition of a need for patient education, each 
agency has its own recommendation for topics to be covered during a patient consultation 
rather than a standard curriculum or set of information. For example, the CDC recognizes 
that patient education is critical before starting opioid therapy so that physicians can have 
an informed discussion surrounding the patient’s treatment (“CDC Guideline for 
Prescribing Opioids for Chronic Pain—United States, 2016,” 2016). The educational 
concepts recommended for use in patient education include: dosage, side effects, 
addiction risk, avoiding alcohol, modifying medications, illegal drugs, epidemiology, 
selling or sharing prescriptions, withdrawal, tolerance, polypharmacy, pharmacokinetics, 
alternative treatments, overdose, safe disposal, tolerance, and dependence (“CDC 
Guideline for Prescribing Opioids for Chronic Pain—United States, 2016,” 2016; FDA 
Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid 
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Analgesics, 2019; “Opioid Safety—Veteran/Patient Education—VHA Pain 
Management,” 2019; “Prescription Opioid Misuse, Heroin, and Fentanyl,” 2019). 
Without basic information about the benefits and risks associated with opioid 
usage, patients struggle to have productive discussions or make informed decisions about 
their pain treatment and rely primarily on the recommendations made by their physicians. 
When patients do not understand their prescribed treatment or medication, they are more 
likely to make mistakes with dosing or polypharmacy interactions.  
Prescriber education surrounding opioids has also received attention from several 
government agencies. As part of the FDA’s Risk Evaluation and Mitigation Strategy 
(REMS), they released a set of recommendations of concepts prescribers should 
understand before prescribing extended-release and long-acting opioids. Part of these 
recommendations include monitoring dosage over time, periodic evaluation of pain goals, 
and a comprehensive list of opioid-related risks (FDA Blueprint for Prescriber Education 
for Extended-Release and Long-Acting Opioid Analgesics, 2019). These 
recommendations were made in an effort to ensure the therapeutic benefits of prescribed 
opioids outweighed the associated risks. 
The Precedent for Educational Intervention in Healthcare 
 The delivery of effective healthcare has long involved the co-administration of 
prescriptive therapies and accompanying information. However, patient education has 
had varying levels of success often predicated on the complexity of the material 
presented and the patient’s reading and comprehension skills (Davis et al., 1990). 
Interestingly, patient reading comprehension appears to have an equal effect on 
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understanding when processing information given orally and in written form (Mayeaux et 
al., 1996). Studies have shown that typical written medical material requires an 11th-grade 
reading level for understanding, while the average patient reads at a 4th or 5th-grade level 
(Davis et al., 1990). Using formal education as a measurement for reading 
comprehension was also shown to be unreliable as patients often score three to four grade 
levels below their last completed year of schooling (Davis et al., 1990). This educational 
gap is also correlated with longer hospital stays and the use of more resources during 
hospitalization (Davis et al., 1990). Therefore, it stands to reason that developing 
effective patient education programs provides an attainable and relatively inexpensive 
means to improve healthcare outcomes. 
 Language barriers also provide a challenge in conveying health 
information effectively. Patients who speak a language other than that of their physician 
often struggle to understand the information presented and have correspondingly lower 
health literacy (Sudore et al., 2009). Translated written material can improve 
communication between physicians and patients, but can ultimately be limited by a 
patient’s reading comprehension. This also must be taken into consideration when a 
patient is asked to give informed consent in a medical office. Important information 
regarding consent and the administration of healthcare are often given in a written form. 
For example, discharge instructions, advanced directive forms, and drug labels may 
require a degree of reading comprehension above that of an average patient.  
 The applicability and necessity of patient education can also depend on the type 
of condition being treated. Managing chronic conditions, like diabetes and high blood 
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pressure, requires long-term maintenance and depends more on a patient’s ability to 
understand and adhere to prescribed treatments (Roumie et al., 2006; Strömberg, 2005). 
Acute conditions on the other hand, like the treatment of infection with antibiotics, 
require short-term compliance and can be successfully treated with less patient education, 
especially if managed entirely by healthcare professionals in a hospital or clinical setting. 
Opioids are unique in that they are used in the management of acute and chronic pain, 
and present a risk of overdose and addiction in both use cases. Therefore, patient 
education with respect to the proper use of opioids could be useful for both acute and 
chronic applications.  
The degree to which patients are responsible for their own care and their ability to 
execute and maintain proper care often determine the success of medical treatment. 
Healthcare professionals can help improve patient outcomes by using patient education to 
improve a patient’s ability to care for themselves. Based on these facts, it would appear 
that there are compelling reasons to develop and deploy effective patient education 
programs with respect to the use of opioids. 
Methods 
Study Design 
 This study was designed to evaluate the efficacy of communicating 
pharmacological concepts related to prescription opioids to patients during a standard 
medical visit. Patients were evaluated before and after an educational intervention in 
order to measure the patients’ understanding of general terms and concepts surrounding 
prescription opioids. They were given a pre-education evaluation to determine their 
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baseline understanding of the material first. Patients were then shown an animated 
educational video based on a script that used material from a variety of sources including 
the FDA, CDC, WHO, AMA, and practicing physicians. The patients were re-evaluated 
after watching the educational video and finishing their scheduled physician visit. The 
educational video and evaluation were available in both English and Spanish. The study 
ran for eight weeks in four private medical clinics in the North Texas region specializing 
in pain management and orthopedic surgery.  
Study Population and Sampling 
The North Texas area, which includes the Dallas-Ft. Worth metropolitan area, 
was selected as the study population. This area has a population size of roughly 7.1 
million people (“North Texas Population Climbs to 7.1 Million,” 2016). The medical 
clinics selected for inclusion in the study primarily specialize in pain management and 
orthopedic or spinal procedures. These specialties were selected based on the higher 
frequency with which patients are treated with prescription opioids for chronic pain or 
acute pain. The medical staff at each of the study locations randomly selected patients to 
participate in the study. The medical staff was advised to discontinue the study if they 
determined that the process was negatively affecting patient visits or quality of care.  
Additionally, patients were able to decline to take part in the study or discontinue the 
study at any time. 
Data Collection 
 The four testing locations were each given four electronic tablets for distribution 
to the randomly selected patients. The medical staff handed out these tablets at the patient 
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sign-in and collected the tablets upon completion of the post-education evaluation. The 
medical staff briefly explained how to use the tablet, what the study was for, and how the 
results would be evaluated. Patients were instructed to finish the post-education 
evaluation after their physician visit. Each of the tablets given to patients was preloaded 
with an application that took the patient through three steps: a baseline evaluation, an 
educational intervention, and a second evaluation identical to the first one. All three steps 
of the study were designed to take between 15 to 20 minutes combined. The evaluation, 
included in Appendix A, was formulated by a team of physicians based on the 
recommendations set forth by government and medical entities including the FDA, CDC, 
VA, AMA, World Health Organization (WHO), as well as the recommendations of 
private researchers and practicing physicians. The evaluation was written at a 5th-grade 
reading level.   
Educational Intervention 
 Each patient watched an animated educational video designed by the research 
team and practicing physicians based on information collected from the FDA, CDC, 
WHO, AMA, and VA. The animated video was produced by the research team and third-
party animator. The final video was 13 minutes in length and covered the following 
topics: 
• Benefits/Risks of Opioids 
• Addiction Risk 
• Dosage 
• Crushing or Modifying Medication 
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• Epidemiology 
• Opioid Withdrawal/Tolerance 
• Pharmacokinetics 
• Polypharmacy 
• Side Effects 
• Avoiding Alcohol 
• Illegal Drug Use 
• Never Share/Sell Medications 
• Open Communication with your Doctor 
• Stopping Opioid Use 
• Do’s and Don’ts of Overdose 
• Naloxone 
• Safe Disposal of Prescriptions 
Data Analysis 
 Data analysis was performed by the research team under the supervision of 
project managing physicians. Slovin’s Formula (n=(N/(1+Ne2)) was used to determine 
the desired sample size. A confidence interval of 95 percent was used in the calculations. 
When imputing the necessary values for population size (N = 7,100,000) and confidence 
level (a = .05), it was determined that a sample size of 400 would be sufficient for 
analysis. Following the collection of data, patient scores for the baseline evaluations were 
compared to the patient scores of the post-education evaluation using a statistical test for 
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matched samples with a continuous outcome. A z-score of 1.96 corresponding to the 95 
percent confidence interval (a = 0.05) was used in the calculations.  
Results 
Organization and Processing of Data 
Patients were surveyed for a total of eight weeks during the months of July, 
August, and September of 2018. In that time period, 478 total responses were collected 
from the four participating locations. A sample of 400 patients was randomly selected 
from the collected data for analysis. Patients scored an average of 34 percent on the first 
evaluation that was given before the educational material was administered. The most 
frequent score was 30 percent with zero of 400 patients achieving a perfect score of 100 
percent. Figure 6 shows the distribution of pre-education evaluation scores. 
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Figure 6: Histogram of evaluation score collected before patients received the scripted 
educational material. 
In post-education evaluations, patients scored an average of 49 percent. The most 
frequently documented score was 60 percent with one of 400 patients scoring 100 
percent. The number of patients that scored zero percent decreased from 24 to 9. Of the 
original 24 patients who score zero percent, 20 improved their score, 4 patients scored 
zero for a second time, and 5 patients who had previously scored 10 percent or higher, 
scored zero percent on the second evaluation. The distribution of post-education 
evaluation scores can be seen in Figure 7. All score values 50 and above increased in the 
post-education evaluation. Overall, patient scores improved an average of 19 points for 
the post-education evaluation. 
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Figure 7: Histogram of evaluation score collected after patients received the scripted 
educational material. 
Combining the two sets of data shows the mean change in test scores was an 
increase of 14.95, with a standard deviation of 18.9. A z-score of 15.85 was calculated for 
a matched samples, continuous outcome statistical test using 400 for the number of 
patients, and calculated values of 18.86 for the standard deviation and 14.95 for the mean 
difference. The calculated z-score is greater than a z-score of 1.96 (a = 0.05) indicating a 
statistically significant improvement in evaluation scores after the educational 
intervention. The pre- and post-education evaluation scores are illustrated in Figure 8. A 
table of raw data used for score calculations can be found in Appendix B. 
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Figure 8: Histogram of evaluation score differences between the first and second 
assessments. 
Conclusion 
Discussion 
 This study was designed to evaluate two important questions related to 
prescription education and the opioid crisis: 1) what the average patient knows about the 
benefits and risks associated with taking prescription opioids, and 2) when presented a 
simple and standardized set of information, whether patients can improve their 
understanding of medical concepts concerning pain management and prescription 
opioids. 
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The results indicate that the average patient in the North Texas area does not have 
a strong understanding of the tested concepts about opioids and pain management as 
represented by the average evaluation score of 30. However, it does appear that after 
participating in the standardized educational program, patients were generally able to 
improve their scores. While an average score of 49 on the post-education evaluation is 
still below the conventional academic standard of a passing grade, the goal of increasing 
patients’ understanding of prescription opioids was still achieved. Increasing the average 
score from 30 to 49 demonstrates an overall improvement of more than 50 percent on 
average for evaluations taken after viewing the educational video. Additionally, the 
number of patients who scored 70 or higher nearly quadrupled from 28 patients to 98 
patients.  
During the study, medical staff observed that patients who had watched the 
educational video were much more likely to ask questions regarding pain management 
and prescription opioids. These patients were able to identify and apply the concepts and 
vocabulary in the video to their condition and treatment plan. Physicians also found that 
they were able to better recognize what patients understood, allowing them to build on 
that information during their medical consultations to better prepare patients for the risk 
of taking prescription opioids.  
The research team is planning to use this information to build an automated 
assessment tool for physicians to use that will identify less medically literate patients as 
well as patients at greater risk for complications related to opioids based on demonstrated 
risk factors and polypharmacy. The goal is to provide physicians with the opportunity to 
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counsel patients more effectively by speaking to educational points that patients typically 
do not understand. This approach could be expanded to other prescription medications 
with a risk for accidental misuse such as benzodiazepines.  
Over the eight-week study, we encountered some challenges that need to be 
addressed before a viable education solution can be implemented on a larger scale. First, 
the medical staff found it difficult to coordinate patient visits when trying to work around 
the 13-minute educational video. This led to increased patient wait time on busy clinic 
days. The second challenge was that patients frequently wanted to leave immediately 
after their medical visit without finishing the educational video and the post-education 
evaluation. To overcome these challenges the research team has decided to divide the 
information and evaluations into shorter sections that can be completed more quickly and 
over several office visits. 
This study also had certain limitations that should be considered before improving 
or continuing the study. The first limitation is the relatively small geographic area (North 
Texas) that was used for sampling. Expanding the sample area to include more of the 
United States would help confirm the applicability of the program across the country. The 
relatively short timeframe of the study also limits our understanding of how well patients 
can retain these concepts over long periods of time. A follow-up study, in which the same 
patients are given the same evaluation at a later date, could provide valuable insight into 
the validity of long-term public health projects dedicated to medical literacy.  
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Summary 
 Opioid addiction, misuse, and overdose continue to be an ever-present threat to 
public health in the United States. Each year a growing number of people lose their lives 
to both prescription and illicit opioids. It will take a concerted effort from a variety of 
parties to adequately address this problem. Politicians and lawyers are scrutinizing the 
actions of pharmaceutical companies, drug distributors, and healthcare providers and are 
working to hold such parties accountable for their actions with respect to opioids. 
Physicians are leveraging technology through PDMPs to identify prescription misuse, 
recognize polypharmacy, and reduce the number of opioid prescriptions written. Drug 
manufacturers are working to develop abuse-resistant formulations of their medications 
and alternative pain therapies. 
Patients can and must also be part of remedying the opioid crisis. Through proper 
and timely education, patients can take greater control of their healthcare and prevent 
accidental overdose and misuse. This education could also prove to be useful in 
preventing the transition from therapeutic opioid use to illicit opioid use. Additionally, 
teaching patients how to properly store and dispose of prescription opioids could help 
reduce the onset of addiction, as many people become addicted taking leftover or 
improperly discarded prescription opioids.  
 A similar patient educational approach could also be expanded to other 
prescription medications that present a risk of misuse and overdose. For example, 
benzodiazepines in the form of Xanax, and amphetamines in the form of Adderall both 
have the potential for abuse and misuse. These drugs can also be found on the street in 
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their prescribed form or in combination with other drugs. Therefore, patients dependent 
on these other types of prescriptions are also at risk of transitioning to illicit drugs; much 
like how prescription opioid users transition to heroin when stricter regulations reduce 
prescribing rates and legal availability. 
Greater emphasis on a proactive approach to address the opioid crisis seems 
imperative. Reductions in prescribing opioids have not had the desired effect and are not 
the solution to preventing general prescription misuse and overdose in the long-term. 
Teaching patients when and how to use prescriptions safely could prove to be a more 
viable strategy in addressing not only the opioid crisis but in preventing similar future 
public health crises involving prescription drugs. 
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APPENDIX A Pre-	and	Post-Education	Evaluation	used	during	the	eight-week	study		
				
Test Questions for Whiteboard Education Module 
 
1. What are prescription opioids used for? 
 
a. The treatment of infection  
b. The treatment of anxiety 
c. The treatment of high cholesterol  
d. The treatment of pain 
e. None of the above 
 
D is the correct answer.  
 
2. What is a sedative? 
a. A stimulating or mood changing drug such as alcohol  
b. A stimulating drug with mood altering effects such as Xanax (anti-anxiety)  
c. A calming or sleep inducing drug such as Ambien (sleeping medication). 
d. A calming and sleep inducing drug such as antibiotics 
e. None of the above 
 
C is the correct answer. 
 
3. How many of the following are sedatives? 
1. Alcohol 
2. Cholesterol medication (Statins) 
3. Xanax (Anti-anxiety) 
4. Opiate Medications 
5. Sleeping Medications 
6. Antidepressants  
7. Allergy Medicine (antihistamines) 
8. Antibiotics  
a) 3 
b) 4 
c) 5 
d) 6 
e) 7 
 
D is the correct answer.  
 
 
 
 
4. Short Acting Opioids and Long Acting Opioids… 
 
a. Contain same medication but differ in how they are released 
b. Have the same effect timeframe and same medication 
c. Have different effects on the body 
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d. Are identical to one another 
e. None of the above 
 
A is the correct answer.  
 
5. The additive effect is… 
 
a) Adding a muscle relaxer to an antibiotic in a pain management program. 
b) The process of testing how two medications are processed in the liver and kidneys. 
c) The compounding effect that medications have on the cardiovascular system when two or 
more medications are prescribed. 
d) When two drugs used in combination produce a combined effect greater than what they 
would individually. 
e) None of the above 
 
D is the correct answer. 
 
6. Which action is safe when taking prescription medications? 
 
a) Share your unused medications with family who are taking the same prescription 
b) Dispose of your prescription in the trash outside of its original container 
c) Chop your pills in half to make them easier to swallow 
d) Discuss increasing the number of drugs you take with your doctor 
e) None of the above 
 
D is the correct answer.  
 
7. Tolerance is… 
a) Dangerous in all situations and should be discussed with your doctor 
b) The first step in recognizing dependence and addiction 
c) The need to increase dose over time after repeated prescription use 
d) An abnormal part of taking opioids for chronic pain 
e) None of the above 
C is the correct answer.  
 
8. Dependence is… 
a) An unavoidable part of taking opioids 
b) The same as addiction 
c) Likely due to patient non-compliance 
d) Characterized by withdrawal symptoms 
e) None of the above 
 
D is the correct answer.  
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9. Which of the following characterizes an opiate? 
1. A Sedative 
2. An Unsafe Medication 
3. A Pain Reliever 
4. A drug only available by injection 
 
a. 1,3 
b. 2,3 
c. 3,4 
d. 1,2,3 
e. None of the above 
 
A is the correct answer.  
 
10. I can safely make my prescription meet my pain needs by doing which of the following: 
 
a. Breaking tablets apart to make them easier to ingest 
b. Increase dosage as needed to manage pain 
c. Doubling next dose to make up for a missed dose 
d. Stopping my prescription because I no longer have pain 
e. None of the above 
 
E is the correct answer.  
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APPENDIX B 
Table of raw data collected during the eight-week study. Pre-Education (Pre-Edu) and 
Post-Education (Post-Edu) are compared to calculate the change in score (Score Delta). 
Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.852550037	 7/17/18	 3:22	PM	 70	 90	 20	
0.619262083	 8/8/18	 9:40	AM	 60	 80	 20	
0.43416853	 7/24/18	 1:36	PM	 50	 80	 30	
0.508845641	 7/31/18	 2:34	PM	 30	 30	 0	
0.51381193	 8/9/18	 10:43	AM	 40	 60	 20	
0.536173617	 8/15/18	 9:27	AM	 80	 80	 0	
0.848542335	 7/27/18	 1:45	PM	 0	 50	 50	
0.443848449	 8/24/18	 9:21	AM	 30	 50	 20	
0.392118387	 7/26/18	 8:58	AM	 30	 10	 -20	
0.632456612	 7/19/18	 9:03	AM	 60	 60	 0	
0.392496611	 8/14/18	 9:43	AM	 50	 60	 10	
0.924249866	 8/8/18	 10:19	AM	 80	 90	 10	
0.318240735	 8/10/18	 9:44	AM	 20	 20	 0	
0.652724653	 8/16/18	 2:18	PM	 50	 60	 10	
0.044931653	 8/10/18	 12:50	PM	 10	 50	 40	
0.389129809	 8/7/18	 4:45	PM	 80	 50	 -30	
0.335426165	 7/26/18	 11:17	AM	 10	 40	 30	
0.190618247	 7/25/18	 9:14	AM	 10	 10	 0	
0.260187511	 7/23/18	 1:09	PM	 0	 20	 20	
0.848247566	 7/16/18	 2:13	PM	 60	 60	 0	
0.384472875	 8/10/18	 8:17	AM	 50	 60	 10	
0.698366921	 8/16/18	 1:57	PM	 10	 30	 20	
0.148142547	 7/17/18	 9:44	AM	 40	 70	 30	
0.508779816	 8/20/18	 1:14	PM	 40	 50	 10	
0.547413589	 8/23/18	 11:59	AM	 40	 60	 20	
0.43918751	 8/7/18	 9:37	AM	 50	 50	 0	
0.645733365	 7/18/18	 10:06	AM	 20	 40	 20	
0.965964624	 8/23/18	 10:03	AM	 60	 80	 20	
0.162498368	 7/17/18	 10:47	AM	 40	 60	 20	
0.991412875	 8/23/18	 2:07	PM	 30	 50	 20	
0.763006415	 8/2/18	 9:54	AM	 10	 10	 0	
0.614317501	 8/27/18	 11:29	AM	 50	 80	 30	
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Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.44405305	 7/18/18	 2:19	PM	 30	 10	 -20	
0.052249254	 8/16/18	 10:52	AM	 10	 30	 20	
0.933914369	 8/2/18	 2:05	PM	 10	 20	 10	
0.622963345	 7/20/18	 8:27	AM	 40	 70	 30	
0.585614382	 7/26/18	 5:47	PM	 40	 40	 0	
0.063008392	 8/20/18	 11:29	AM	 70	 80	 10	
0.800821581	 7/18/18	 10:18	AM	 0	 10	 10	
0.86157053	 7/16/18	 9:08	AM	 10	 30	 20	
0.266928818	 9/4/18	 1:41	PM	 50	 50	 0	
0.9133873	 7/16/18	 1:06	PM	 10	 70	 60	
0.776060594	 8/15/18	 9:34	AM	 40	 60	 20	
0.438923725	 7/20/18	 12:38	PM	 30	 70	 40	
0.927394701	 8/16/18	 2:21	PM	 80	 70	 -10	
0.631468059	 7/31/18	 10:42	AM	 30	 40	 10	
0.333249305	 7/23/18	 11:41	AM	 20	 60	 40	
0.384985641	 8/14/18	 11:00	AM	 40	 70	 30	
0.931825724	 8/10/18	 4:33	PM	 50	 40	 -10	
0.916361681	 8/2/18	 4:24	PM	 20	 30	 10	
0.198707924	 7/20/18	 12:20	PM	 20	 30	 10	
0.571678535	 7/25/18	 9:27	AM	 50	 80	 30	
0.287696374	 9/4/18	 2:07	PM	 20	 60	 40	
0.741633598	 7/27/18	 2:52	PM	 10	 30	 20	
0.450828343	 7/24/18	 8:32	AM	 30	 50	 20	
0.835648089	 8/7/18	 10:06	AM	 70	 60	 -10	
0.774033839	 7/25/18	 2:51	PM	 30	 50	 20	
0.783490675	 8/2/18	 2:07	PM	 30	 70	 40	
0.364211629	 7/20/18	 2:32	PM	 30	 40	 10	
0.256906954	 7/24/18	 10:36	AM	 20	 60	 40	
0.782994439	 7/24/18	 8:37	AM	 30	 50	 20	
0.779835306	 7/23/18	 9:00	AM	 40	 60	 20	
0.066223128	 8/9/18	 10:51	AM	 40	 40	 0	
0.710322041	 8/24/18	 12:08	PM	 30	 40	 10	
0.099770089	 8/23/18	 9:30	AM	 30	 40	 10	
0.934578819	 8/2/18	 8:52	AM	 30	 50	 20	
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Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.064177804	 8/7/18	 9:15	AM	 20	 70	 50	
0.728405032	 8/10/18	 11:05	AM	 90	 90	 0	
0.043352298	 7/27/18	 10:54	AM	 40	 70	 30	
0.158362503	 7/17/18	 4:40	PM	 0	 10	 10	
0.033867384	 8/7/18	 1:58	PM	 50	 60	 10	
0.643245012	 8/9/18	 9:07	AM	 30	 70	 40	
0.902375594	 8/10/18	 9:04	AM	 70	 50	 -20	
0.872083609	 8/8/18	 10:08	AM	 60	 70	 10	
0.792819974	 8/17/18	 2:02	PM	 70	 90	 20	
0.04477537	 8/21/18	 9:48	AM	 40	 40	 0	
0.03786674	 8/31/18	 2:32	PM	 50	 40	 -10	
0.058184309	 8/7/18	 9:00	AM	 20	 50	 30	
0.185451824	 8/8/18	 11:32	AM	 20	 60	 40	
0.806940029	 7/27/18	 1:48	PM	 30	 40	 10	
0.081088115	 7/27/18	 10:54	AM	 0	 0	 0	
0.808474593	 7/18/18	 11:20	AM	 20	 20	 0	
0.695381708	 7/16/18	 2:29	PM	 20	 20	 0	
0.54539772	 8/21/18	 4:04	PM	 30	 30	 0	
0.811347083	 8/13/18	 9:41	AM	 20	 50	 30	
0.148427447	 7/27/18	 2:39	PM	 30	 20	 -10	
0.957175098	 7/19/18	 8:17	AM	 30	 60	 30	
0.349006316	 7/17/18	 1:32	PM	 10	 40	 30	
0.973864093	 8/21/18	 1:50	PM	 20	 60	 40	
0.382135712	 8/2/18	 9:01	AM	 60	 70	 10	
0.2457341	 7/31/18	 9:46	AM	 20	 40	 20	
0.634548393	 8/10/18	 11:10	AM	 40	 70	 30	
0.631159102	 8/9/18	 11:16	AM	 40	 60	 20	
0.163290628	 8/17/18	 1:35	PM	 50	 70	 20	
0.891035637	 7/19/18	 9:06	AM	 30	 50	 20	
0.186905906	 7/23/18	 8:57	AM	 30	 20	 -10	
0.77430101	 7/27/18	 1:42	PM	 60	 70	 10	
0.936987036	 7/26/18	 2:50	PM	 40	 60	 20	
0.457137285	 7/18/18	 11:09	AM	 80	 80	 0	
0.113238736	 7/19/18	 2:57	PM	 20	 40	 20	
 
 
		 54	
APPENDIX B (cont.) 
Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.07997284	 7/27/18	 2:10	PM	 30	 60	 30	
0.494396252	 8/2/18	 9:40	AM	 0	 10	 10	
0.735789689	 8/2/18	 11:35	AM	 50	 50	 0	
0.084479752	 8/8/18	 8:50	AM	 50	 40	 -10	
0.899317182	 8/31/18	 12:02	PM	 30	 40	 10	
0.560767541	 8/7/18	 1:35	PM	 60	 70	 10	
0.745057136	 8/2/18	 10:39	AM	 0	 70	 70	
0.118621504	 7/30/18	 11:07	AM	 10	 20	 10	
0.294563801	 8/8/18	 3:25	PM	 60	 80	 20	
0.080681955	 8/9/18	 2:31	PM	 80	 90	 10	
0.04764101	 7/31/18	 10:43	AM	 20	 60	 40	
0.921027339	 7/19/18	 9:16	AM	 20	 30	 10	
0.902812814	 8/23/18	 8:35	AM	 50	 90	 40	
0.823984182	 8/29/18	 2:06	PM	 10	 70	 60	
0.361327449	 7/17/18	 8:52	AM	 30	 30	 0	
0.31523456	 8/31/18	 1:18	PM	 40	 10	 -30	
0.703731658	 8/24/18	 12:03	PM	 40	 30	 -10	
0.776466545	 8/24/18	 1:07	PM	 30	 60	 30	
0.843147764	 7/19/18	 9:00	AM	 30	 20	 -10	
0.103776504	 8/3/18	 9:38	AM	 40	 40	 0	
0.550915553	 8/21/18	 2:56	PM	 30	 40	 10	
0.985463922	 8/15/18	 9:18	AM	 40	 40	 0	
0.664884602	 7/19/18	 10:33	AM	 30	 30	 0	
0.288065213	 7/19/18	 11:28	AM	 50	 60	 10	
0.298270399	 7/18/18	 11:55	AM	 70	 60	 -10	
0.193840121	 8/23/18	 1:32	PM	 20	 40	 20	
0.742270853	 7/19/18	 9:34	AM	 30	 60	 30	
0.58027009	 7/18/18	 8:53	AM	 50	 10	 -40	
0.34436429	 7/24/18	 9:41	AM	 30	 50	 20	
0.149409287	 8/16/18	 3:42	PM	 40	 50	 10	
0.950196423	 8/17/18	 12:35	PM	 20	 20	 0	
0.038345075	 7/24/18	 11:24	AM	 60	 80	 20	
0.940171063	 8/2/18	 2:43	PM	 50	 60	 10	
0.620060362	 8/13/18	 1:24	PM	 70	 90	 20	
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Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.329824763	 8/16/18	 9:20	AM	 0	 90	 90	
0.010093952	 7/19/18	 11:01	AM	 40	 50	 10	
0.55506403	 7/16/18	 10:55	AM	 40	 60	 20	
0.248416172	 8/7/18	 10:34	AM	 10	 40	 30	
0.628334588	 7/31/18	 2:53	PM	 10	 40	 30	
0.711379127	 8/16/18	 3:53	PM	 30	 30	 0	
0.525405669	 8/2/18	 2:50	PM	 50	 60	 10	
0.837625703	 7/24/18	 8:50	AM	 40	 60	 20	
0.472139514	 8/10/18	 3:23	PM	 10	 30	 20	
0.312298641	 8/14/18	 11:37	AM	 40	 50	 10	
0.522951182	 8/7/18	 1:28	PM	 30	 40	 10	
0.18861331	 8/31/18	 11:11	AM	 10	 10	 0	
0.558899127	 8/1/18	 2:34	PM	 10	 30	 20	
0.283153025	 7/19/18	 9:22	AM	 30	 60	 30	
0.196862672	 9/4/18	 3:39	PM	 40	 30	 -10	
0.30328387	 8/17/18	 2:10	PM	 70	 70	 0	
0.355650516	 8/21/18	 4:22	PM	 80	 70	 -10	
0.091410831	 7/16/18	 1:53	PM	 0	 20	 20	
0.801848894	 8/8/18	 11:01	AM	 10	 40	 30	
0.51023181	 8/1/18	 2:07	PM	 60	 80	 20	
0.652009686	 8/8/18	 11:00	AM	 40	 50	 10	
0.550619037	 8/8/18	 10:29	AM	 20	 20	 0	
0.55341371	 8/28/18	 9:08	AM	 30	 40	 10	
0.188560674	 8/7/18	 8:10	AM	 40	 30	 -10	
0.782619215	 8/15/18	 2:15	PM	 70	 70	 0	
0.208679237	 8/22/18	 10:40	AM	 80	 90	 10	
0.070265781	 8/8/18	 9:15	AM	 50	 80	 30	
0.757900334	 8/9/18	 1:28	PM	 40	 60	 20	
0.515609376	 8/8/18	 2:20	PM	 10	 40	 30	
0.375555596	 7/24/18	 9:16	AM	 40	 10	 -30	
0.746932544	 7/20/18	 10:06	AM	 40	 60	 20	
0.069611715	 7/19/18	 9:56	AM	 20	 30	 10	
0.77900895	 8/10/18	 12:26	PM	 30	 20	 -10	
0.53791838	 7/26/18	 1:52	PM	 10	 20	 10	
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Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.590344074	 7/26/18	 4:15	PM	 10	 20	 10	
0.357910018	 8/14/18	 3:03	PM	 20	 60	 40	
0.932773117	 7/31/18	 1:40	PM	 30	 20	 -10	
0.50230028	 8/20/18	 1:11	PM	 50	 40	 -10	
0.766028469	 7/25/18	 4:28	PM	 30	 60	 30	
0.735409324	 8/17/18	 11:58	AM	 50	 30	 -20	
0.079489525	 8/16/18	 10:14	AM	 80	 80	 0	
0.560426354	 7/23/18	 9:49	AM	 60	 60	 0	
0.60584088	 8/27/18	 11:19	AM	 10	 50	 40	
0.947703682	 8/14/18	 2:44	PM	 20	 30	 10	
0.810646272	 8/8/18	 11:08	AM	 0	 10	 10	
0.039299327	 8/1/18	 2:25	PM	 50	 60	 10	
0.587729546	 7/26/18	 1:29	PM	 60	 60	 0	
0.920991588	 7/24/18	 8:29	AM	 40	 80	 40	
0.346391407	 7/31/18	 9:13	AM	 60	 60	 0	
0.429431347	 8/8/18	 9:03	AM	 50	 70	 20	
0.352566056	 7/27/18	 12:58	PM	 20	 30	 10	
0.967240477	 7/31/18	 1:44	PM	 40	 30	 -10	
0.330849664	 7/31/18	 8:36	AM	 40	 60	 20	
0.694258947	 8/8/18	 10:22	AM	 10	 40	 30	
0.234855284	 7/20/18	 10:05	AM	 60	 50	 -10	
0.92667732	 8/16/18	 4:03	PM	 80	 90	 10	
0.381496087	 7/24/18	 9:02	AM	 40	 40	 0	
0.010726869	 8/8/18	 11:52	AM	 20	 60	 40	
0.295166482	 8/14/18	 1:42	PM	 20	 30	 10	
0.897117879	 7/25/18	 2:33	PM	 0	 70	 70	
0.445909393	 8/10/18	 2:26	PM	 20	 10	 -10	
0.168303912	 8/13/18	 9:18	AM	 30	 40	 10	
0.683996147	 8/22/18	 9:20	AM	 60	 60	 0	
0.775379555	 7/20/18	 2:27	PM	 60	 70	 10	
0.553439895	 8/7/18	 11:32	AM	 30	 40	 10	
0.872437877	 8/3/18	 4:14	PM	 50	 60	 10	
0.367365224	 7/23/18	 10:02	AM	 10	 60	 50	
0.281758077	 7/18/18	 9:11	AM	 50	 70	 20	
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Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.531794558	 7/18/18	 9:24	AM	 50	 60	 10	
0.653752005	 7/27/18	 12:14	PM	 0	 40	 40	
0.352574602	 8/10/18	 2:08	PM	 20	 80	 60	
0.221348665	 8/6/18	 2:32	PM	 20	 20	 0	
0.133889478	 8/9/18	 2:28	PM	 20	 20	 0	
0.453541917	 8/6/18	 11:13	AM	 10	 40	 30	
0.189883897	 7/20/18	 3:06	PM	 80	 80	 0	
0.770943516	 8/23/18	 3:44	PM	 50	 60	 10	
0.527914392	 8/10/18	 10:22	AM	 50	 90	 40	
0.132196944	 7/20/18	 10:48	AM	 10	 30	 20	
0.648803392	 7/20/18	 2:13	PM	 30	 90	 60	
0.793799845	 8/14/18	 3:07	PM	 30	 50	 20	
0.463131729	 8/24/18	 11:36	AM	 30	 30	 0	
0.884722588	 8/29/18	 9:08	AM	 20	 10	 -10	
0.727224743	 7/25/18	 3:02	PM	 10	 50	 40	
0.677701526	 7/18/18	 11:42	AM	 40	 50	 10	
0.215325789	 7/30/18	 2:41	PM	 50	 70	 20	
0.078230008	 7/18/18	 8:56	AM	 30	 70	 40	
0.757872135	 8/2/18	 2:19	PM	 50	 40	 -10	
0.725849814	 7/24/18	 10:39	AM	 10	 40	 30	
0.07896529	 8/2/18	 12:48	PM	 50	 70	 20	
0.161942964	 7/20/18	 2:05	PM	 30	 60	 30	
0.577966846	 8/17/18	 12:34	PM	 50	 50	 0	
0.621012349	 8/6/18	 10:44	AM	 10	 30	 20	
0.655896478	 8/14/18	 1:18	PM	 10	 30	 20	
0.655587854	 8/7/18	 10:02	AM	 10	 50	 40	
0.405695642	 7/23/18	 9:51	AM	 50	 80	 30	
0.492820952	 7/17/18	 9:04	AM	 40	 70	 30	
0.888754951	 8/9/18	 2:11	PM	 0	 10	 10	
0.669458368	 8/13/18	 1:56	PM	 20	 30	 10	
0.733600359	 8/10/18	 2:35	PM	 60	 70	 10	
0.951893823	 8/7/18	 1:51	PM	 20	 50	 30	
0.581630012	 8/16/18	 10:26	AM	 10	 30	 20	
0.479140474	 7/19/18	 1:39	PM	 30	 30	 0	
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APPENDIX B (cont.) 
Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.233992845	 8/16/18	 10:34	AM	 10	 30	 20	
0.84487834	 7/16/18	 3:03	PM	 60	 70	 10	
0.115498277	 8/16/18	 2:47	PM	 0	 0	 0	
0.005354573	 7/18/18	 2:08	PM	 40	 60	 20	
0.46878315	 8/3/18	 1:46	PM	 30	 30	 0	
0.885470187	 7/24/18	 1:13	PM	 40	 30	 -10	
0.242462391	 7/26/18	 10:28	AM	 40	 30	 -10	
0.219463094	 7/25/18	 3:09	PM	 30	 60	 30	
0.595218142	 8/15/18	 3:42	PM	 30	 40	 10	
0.582418992	 8/15/18	 3:43	PM	 20	 20	 0	
0.333144545	 8/22/18	 9:14	AM	 0	 10	 10	
0.509876335	 8/2/18	 10:50	AM	 20	 20	 0	
0.953423991	 8/17/18	 2:00	PM	 30	 60	 30	
0.949595616	 7/16/18	 9:19	AM	 40	 50	 10	
0.478245542	 7/25/18	 3:29	PM	 10	 30	 20	
0.162882774	 7/20/18	 8:55	AM	 20	 40	 20	
0.645077108	 8/21/18	 10:02	AM	 50	 80	 30	
0.083839622	 8/9/18	 10:22	AM	 10	 30	 20	
0.101143627	 8/9/18	 1:06	PM	 0	 0	 0	
0.573401061	 7/16/18	 3:40	PM	 10	 30	 20	
0.966894821	 8/20/18	 1:19	PM	 50	 60	 10	
0.358968312	 7/23/18	 11:33	AM	 30	 30	 0	
0.679190009	 8/9/18	 8:35	AM	 20	 70	 50	
0.994147533	 8/20/18	 10:21	AM	 40	 60	 20	
0.023823411	 7/20/18	 3:02	PM	 30	 30	 0	
0.143284442	 8/9/18	 10:49	AM	 40	 70	 30	
0.369721754	 7/19/18	 3:08	PM	 30	 30	 0	
0.498467963	 7/17/18	 1:29	PM	 50	 50	 0	
0.77248446	 7/25/18	 4:07	PM	 40	 0	 -40	
0.736585604	 7/31/18	 2:38	PM	 20	 20	 0	
0.857162304	 7/30/18	 9:07	AM	 60	 90	 30	
0.413642167	 7/24/18	 3:02	PM	 30	 60	 30	
0.556871706	 8/14/18	 9:59	AM	 20	 50	 30	
0.5789744	 8/6/18	 8:39	AM	 40	 70	 30	
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APPENDIX B (cont.) 
Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.19858361	 8/6/18	 9:29	AM	 20	 30	 10	
0.171656639	 8/16/18	 3:01	PM	 60	 40	 -20	
0.004971816	 7/19/18	 2:17	PM	 40	 80	 40	
0.979904535	 8/29/18	 11:04	AM	 60	 70	 10	
0.269275446	 7/19/18	 4:19	PM	 40	 50	 10	
0.926755262	 8/10/18	 12:22	PM	 30	 30	 0	
0.641171599	 7/26/18	 1:36	PM	 20	 70	 50	
0.323783729	 8/16/18	 9:26	AM	 60	 70	 10	
0.976026982	 8/10/18	 9:59	AM	 10	 10	 0	
0.702574345	 8/7/18	 9:00	AM	 60	 80	 20	
0.335622275	 7/20/18	 10:50	AM	 50	 80	 30	
0.680352898	 7/16/18	 3:48	PM	 10	 50	 40	
0.857516889	 7/18/18	 11:30	AM	 30	 60	 30	
0.774318099	 7/23/18	 1:13	PM	 30	 40	 10	
0.165605503	 7/23/18	 11:02	AM	 30	 50	 20	
0.15529814	 8/16/18	 9:49	AM	 40	 50	 10	
0.948882919	 8/14/18	 2:25	PM	 40	 60	 20	
0.183120512	 7/18/18	 10:50	AM	 80	 100	 20	
0.228524728	 8/31/18	 2:07	PM	 10	 30	 20	
0.079626695	 7/16/18	 9:50	AM	 40	 60	 20	
0.237161405	 8/21/18	 3:17	PM	 30	 60	 30	
0.177781145	 7/16/18	 9:21	AM	 30	 30	 0	
0.054719649	 8/14/18	 3:28	PM	 40	 70	 30	
0.87436177	 8/17/18	 12:11	PM	 70	 80	 10	
0.155229521	 8/14/18	 9:34	AM	 50	 40	 -10	
0.06281383	 8/29/18	 3:25	PM	 20	 70	 50	
0.138795456	 7/26/18	 11:21	AM	 50	 50	 0	
0.33543798	 8/22/18	 4:15	PM	 60	 70	 10	
0.730628455	 8/2/18	 2:49	PM	 30	 50	 20	
0.001834864	 8/16/18	 11:12	AM	 40	 40	 0	
0.203455681	 7/16/18	 8:55	AM	 50	 60	 10	
0.033779222	 7/17/18	 3:44	PM	 50	 60	 10	
0.642675446	 7/17/18	 10:34	AM	 20	 60	 40	
0.896743324	 7/17/18	 2:55	PM	 0	 90	 90	
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Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.271234675	 8/14/18	 10:39	AM	 20	 50	 30	
0.310073094	 8/20/18	 9:21	AM	 50	 40	 -10	
0.739823755	 7/18/18	 9:32	AM	 30	 60	 30	
0.905454674	 8/10/18	 12:24	PM	 10	 20	 10	
0.563978705	 8/2/18	 3:26	PM	 30	 0	 -30	
0.755136542	 7/17/18	 12:06	PM	 30	 30	 0	
0.040825956	 8/31/18	 1:06	PM	 50	 70	 20	
0.800146889	 8/30/18	 3:02	PM	 60	 60	 0	
0.880103146	 8/10/18	 1:56	PM	 60	 70	 10	
0.585183168	 7/18/18	 10:59	AM	 10	 0	 -10	
0.818369983	 7/26/18	 8:42	AM	 20	 10	 -10	
0.657179053	 8/7/18	 3:24	PM	 10	 40	 30	
0.607643119	 8/20/18	 11:36	AM	 20	 30	 10	
0.342774321	 7/23/18	 9:36	AM	 30	 60	 30	
0.337464984	 7/20/18	 8:49	AM	 20	 80	 60	
0.362798413	 7/25/18	 3:32	PM	 60	 70	 10	
0.610437781	 8/15/18	 2:06	PM	 10	 0	 -10	
0.228620672	 7/17/18	 11:03	AM	 50	 60	 10	
0.122162805	 7/27/18	 1:17	PM	 20	 20	 0	
0.532957092	 7/25/18	 1:55	PM	 50	 70	 20	
0.952160533	 7/16/18	 2:43	PM	 90	 50	 -40	
0.511592487	 7/23/18	 11:06	AM	 40	 40	 0	
0.118537571	 8/10/18	 4:08	PM	 20	 40	 20	
0.785752739	 7/25/18	 2:01	PM	 40	 50	 10	
0.746386045	 8/15/18	 9:56	AM	 30	 30	 0	
0.221005539	 7/19/18	 9:55	AM	 10	 40	 30	
0.664951242	 8/2/18	 1:21	PM	 60	 90	 30	
0.570537749	 7/18/18	 9:50	AM	 0	 0	 0	
0.657432111	 7/31/18	 10:36	AM	 20	 40	 20	
0.803918306	 8/20/18	 8:46	AM	 30	 50	 20	
0.906404629	 7/31/18	 10:26	AM	 10	 60	 50	
0.491168185	 7/27/18	 9:06	AM	 30	 70	 40	
0.672760938	 7/16/18	 10:10	AM	 20	 60	 40	
0.76808295	 8/21/18	 2:38	PM	 50	 60	 10	
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Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.471445791	 7/26/18	 1:32	PM	 30	 40	 10	
0.922369106	 8/7/18	 1:53	PM	 70	 70	 0	
0.351953403	 7/30/18	 11:40	AM	 10	 60	 50	
0.618565626	 7/27/18	 9:14	AM	 10	 50	 40	
0.06906823	 7/26/18	 10:34	AM	 10	 20	 10	
0.828610628	 8/10/18	 1:09	PM	 40	 30	 -10	
0.416343519	 8/27/18	 1:49	PM	 60	 60	 0	
0.34765694	 7/26/18	 2:54	PM	 10	 20	 10	
0.547590823	 8/14/18	 10:24	AM	 0	 20	 20	
0.716073599	 8/7/18	 4:06	PM	 50	 70	 20	
0.59401479	 7/18/18	 1:22	PM	 40	 40	 0	
0.346677283	 8/7/18	 10:31	AM	 0	 40	 40	
0.618588393	 8/21/18	 4:39	PM	 50	 70	 20	
0.993253471	 7/17/18	 9:50	AM	 20	 30	 10	
0.874402421	 8/7/18	 11:03	AM	 20	 30	 10	
0.824675159	 7/18/18	 9:30	AM	 30	 50	 20	
0.954556063	 8/8/18	 9:46	AM	 10	 50	 40	
0.054516359	 7/27/18	 2:44	PM	 50	 90	 40	
0.534316399	 7/18/18	 10:03	AM	 10	 60	 50	
0.810976988	 7/19/18	 9:03	AM	 0	 20	 20	
0.016422321	 8/14/18	 9:19	AM	 30	 40	 10	
0.650313399	 8/10/18	 1:12	PM	 70	 50	 -20	
0.980292856	 7/20/18	 12:06	PM	 60	 90	 30	
0.191750039	 8/6/18	 10:35	AM	 40	 20	 -20	
0.266147312	 7/20/18	 2:41	PM	 60	 90	 30	
0.723960328	 8/20/18	 2:29	PM	 40	 40	 0	
0.781628614	 7/16/18	 3:43	PM	 10	 40	 30	
0.68111732	 8/15/18	 3:33	PM	 90	 80	 -10	
0.795589086	 7/17/18	 9:48	AM	 60	 80	 20	
0.040651406	 9/4/18	 10:44	AM	 30	 60	 30	
0.84286178	 8/8/18	 8:57	AM	 60	 60	 0	
0.864311578	 7/18/18	 9:33	AM	 40	 80	 40	
0.248576002	 8/20/18	 1:27	PM	 40	 20	 -20	
0.956011665	 7/18/18	 2:02	PM	 20	 0	 -20	
 
 
		 62	
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Randomized	ID	 Date	 Time	 Pre-Edu	 Post-Edu	 Score	Delta	
0.430659587	 8/14/18	 11:09	AM	 0	 20	 20	
0.053014993	 7/30/18	 10:16	AM	 30	 50	 20	
0.391932821	 7/20/18	 2:31	PM	 20	 30	 10	
0.633079727	 8/2/18	 4:59	PM	 10	 40	 30	
0.030160075	 7/20/18	 12:51	PM	 40	 70	 30	
0.320758515	 7/25/18	 1:55	PM	 30	 20	 -10	
0.888747409	 7/23/18	 11:12	AM	 40	 50	 10	
0.536974199	 8/29/18	 11:07	AM	 20	 70	 50	
0.075323704	 7/20/18	 12:03	PM	 0	 30	 30	
0.25961981	 8/8/18	 11:52	AM	 10	 40	 30	
0.139196102	 7/19/18	 3:35	PM	 30	 40	 10	
0.230855204	 7/31/18	 10:23	AM	 20	 30	 10	
0.264622177	 7/25/18	 9:10	AM	 40	 50	 10	
0.33161268	 8/15/18	 4:26	PM	 10	 50	 40	
0.15405511	 8/10/18	 9:01	AM	 60	 60	 0	
0.765877815	 8/1/18	 1:32	PM	 50	 60	 10	
0.390693446	 8/2/18	 9:05	AM	 30	 40	 10	
0.30711196	 8/9/18	 3:37	PM	 50	 60	 10	
0.035372998	 7/19/18	 10:40	AM	 40	 60	 20	
0.106153324	 8/7/18	 10:56	AM	 0	 50	 50	
0.623210876	 7/26/18	 9:52	AM	 60	 80	 20	
0.204016752	 7/23/18	 8:39	AM	 70	 80	 10	
0.00190454	 7/17/18	 2:54	PM	 20	 50	 30	
0.155455105	 8/7/18	 9:45	AM	 20	 70	 50	
0.259165702	 8/7/18	 1:27	PM	 20	 20	 0	
0.809711449	 7/27/18	 10:01	AM	 30	 40	 10	
0.703535502	 8/24/18	 12:03	PM	 10	 10	 0	
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